HUE026644T2 - Mixtúra alacsony és magas molekulatömegû vegyületek transzdermális beadásához - Google Patents

Mixtúra alacsony és magas molekulatömegû vegyületek transzdermális beadásához Download PDF

Info

Publication number
HUE026644T2
HUE026644T2 HUE05826138A HUE05826138A HUE026644T2 HU E026644 T2 HUE026644 T2 HU E026644T2 HU E05826138 A HUE05826138 A HU E05826138A HU E05826138 A HUE05826138 A HU E05826138A HU E026644 T2 HUE026644 T2 HU E026644T2
Authority
HU
Hungary
Prior art keywords
transdermal delivery
acid
composition
skin
collagen
Prior art date
Application number
HUE05826138A
Other languages
English (en)
Inventor
Frederick Jordan
Geoff E Dolbear
Original Assignee
Oryxe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/017169 external-priority patent/WO2005039464A1/en
Priority claimed from US10/856,567 external-priority patent/US7220427B2/en
Application filed by Oryxe filed Critical Oryxe
Publication of HUE026644T2 publication Critical patent/HUE026644T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (17)

1 > Llpí%őmböt tartalmadé, borön M. mkalmazható készimény, ahol a%îâg0iA SMxitei xsircsoporiol vágy Jipdeseportot. és egy alkalmazott hatóanyagot Äalmaz, ahol a zsiresőport vagy llpídesopert eîoxilezésének tâ&tôké lík 11,; í% 13,: 14, 1¾ 16, 17, IS vagy 19 etmeíezés n»lekeiánkéni, és ahol & zsírcsoport: vagy lípkfcsopmt 19 szén maradékot tartalmaz, Z Μ 1* igénypont szerinti Hin ât alkaimtótato |êsÂÉ8y> amely tartalmaz további vizet.
3. Az 1. igénypont szériát!: i# át alkalmazbatp készítmény amely tartalmaz mváböá alkoholt,
4. Az !... igénypont szerinti: hitön É: alkalmazható készítmény, állöl: a zsiresoport vagy IpiáesopóÉ legalább 1:9 mm maradékok. de légijeié 39 szén matádékrtí tartalmaz,
5. Az 1. igénypont szerinti My& É alkalmazható készítmény, alól az etoxilezés :mennylsege ngyanakkom, rmot a zsitcsoporí: vagy lipide söpört szén mmarlékaipal száma,
6. Az 1, igénypont szerinti horda ai altelmazhato készítmény, alól a zslmsopop vagy iipidesoport MnckosszÉsága 19,12, 14. 16,18,20, 22 vagy 24 szén maradék.
7. Az 1. igénypont szerinti borin át alkalmazható készítmény, ahol a zsírcsoport egy zsírsav. Ü. A 7. igénypont szerinti bitón át alkalmazható készítmény, ahol a zsírsav az alábbiak köréből választott: Cl 6:1, dalla 1; €16:1, delta 2; €16:1, delta 3; €16:1, delta 4; Cl 6:1, delta 3; €19:1, delta 6; C16;l, delta 7; €16:1, delta i:; ClJtl, delta 9 fpalmimlsavy; €16: k delta 10; €16:1, deka 11; €16:1, delta 12; €16:1, delta 13; és €16:1, delta 14. % Az l. Igénypont szérini bőrön át alkalmazható készítmény, ahol á xsíresopert egy zsír-amin, 10; Az igénypont szerinti bőrön át alkalmazható kéSZlhnénl, aboi a lipidesopori szingoltpd, g!lc?llprd vagy glikoszlingolipid.
11. Az: 1. Igénypont szerinti boron al alkalmazható készítmény, ahol a lipldgomb etoxiiezett zsircsoport homogén keverékét, vagy etoxiiezett zsírsavak heterogén keverékét tartalmazza.
12. Az 1. igénypont szerinti bőrön át alkalmazható készítmény, ahol az alkalmazott hatóanyag egy poiipeptid hormon.
13. Az 1. igénypont szerinti bőrön át alMtmtzható készítmény, ahol az alkalmazott hatóanyag kollagén. 14. : Az í. Igénypont smánti bőrön ál alkalmazható készítmény, ahol az alkalmazott hatóanyag: egy érzéstelenítő,
15.. Az X, Igénypont szerinti bőrön át a&almazható készítmény, ahol az alkalmazott Itatóanyag: egy fajdalomcsillapitó,
14. Az 1. Igénypont szerinti bőrön |t alkalmazható készítmény, ahol m alkalntazott hatóanyag egy rmnöszleroid gyulladáscsökkentő hatóanyag (NSA1D) azmláhthak-kötóhől választva: ihnptolen (2~(Ízőhntilfenii)--proplonsav}; ntelotrexat (N-[4~{2:, 4 dlamino 4 * ptóidtói ~ rnetil] metilatnlno] henzoilkL-glhttó«^. aszpirin iaeetlszaleilsav); szalkilsav; dilenkidranún .(2n(Éifenílm«^ sosav):;: naproxén p-nailalén eeetsav, ő-Tnetózi-ü-métE", námnmsó, (*) "$: femlhutazon f4-buti i-1 szoItódak^(2|'5-:nno^2^nmí|l~l-[|;p'«(metiiszultínii}feíiiljníeíilén~|~lll»mdén'3-eéeisav; íiinnizál (2',4\ ^diiuor-d-hídroxírdtóitenilkarboxilsav; piroxkam 2-'heitóotiatón^2rkarbo:xamíd 1, 1-dioxid, oxiesny Indometadn |1-(4-którbenml|}»S” metóxn2ns€til4lrindol'-3'-eeetsavl:; meUofenamál nátrium |Nr(2, Mlklor-mAolE) antmnilsav, náirímnsó, nmnohidraík ketoprotón PA3"benzoílfeml)-pmpÍönsao| lóiméin Bâtions ípátém .1 »moiltó^nÉgílbenzoíl-1 H^Mí>2-acetát dihldrát); diklotérák-nátrium (2~|p,,i-diklórfenil:)amísmltóenzoieemsay mononátrium sók hldroxiklorokin szullát í2iP-|12>>:klőrtó”kinnliI)ahtinolpentiÍ] eíilarninoletano! szollat (1;!); penieíllamm tó-merkapto^P-yálin); ílnrhlprolen {[l.tóhitónij-d-ecetsav, 2-Íoormlfemeil-, (4--); ©lodolak {i4-dtóti!-l3,4,1, íetrahidröplrano'ptó-fölindoktóeeefeax; mvíenamlnsav (hí·· (2J-> dlil)aníraníbav; és ditóntódrarnln sósav ptóiíenl metoxi-N, Ntói-metlletanán sósav).
13, Az 1:, igénypont szeinlt boron $.t alkalmazható Mszíhsény,: ahol az alkalmazott hatóanyag egy gyuHadásosÖkkentó vegyület Ihdrőkortízön, predntzólon, Iriamcínoten, korüzon és piroxikám köréből választva, vagy egy fertőtlenítő vegyük? amoxicillin, klavolinát-kállssp: iírakonazoi;, aeiklovh; hnkonazol, mMmün sósav, entromiéin Piszokéinak aoeiil sxulrizoxazol, penicillin % eetólexm, ©riíromfem, aziîmmioin, Mraslklis, eipMSaxm,: gemamícin, szulfaüazol, m^ofmmî^%: norioxaem, flumekvip. és. Ibaioxacíu, rneíromdazol, nisziarin, kmivudin, indinavir szaliai, és smvodm köréből választva. 14 Az 1 igénypont szerinti hirön át alkalmazható készítmény, ate! m alkalmazott hatóanyag metíormín sósav vagy akarbóz,
19. Az 1. Igénypont szerinti bőrön át alkalmazható készítmény, ahol m. alkalmazott hatóanyag: egy immunogén, példán! egy pokmjkléötidoí tartalmazó immunogen. 24 Az 1, igénypont szerinti bőrén át alkalmazható készítmény, ahol az alkalmazott: hatóanyag égy immunválaszt módosító anyag:. 1L Az 1. igénypont szerinti bőrön It alkalmazható lészítmény, ahol m alkalmazod hatóanyag égy enzim inhibitor zileaton* kaptopril. és fízioopil Imréből válhatva; vagy a hatóanyag otgotamia, melatonin, szumairipián, zohnítripiáo, és rizatriptan köréből választóit' vagy pipidet», zíílpsdem-tartarát, triazolam, & Ihcoszein-bmiítemhl köréből választóit ; vagy jobexol, teehneolnm, Ä9!%£ sestamiki JomeproL gadodiamld, joverzol, és jopromid köréből választóit; vagy aizakttd, amerieiom, betazol, hisztamim mannit, mériPpOP, pétagaszhin, tentóiamin, radioaktív B12, gadodiamah gadopentetmsav, gadoteriiöl, priukron, cihlosporín, szlldenatl! eltiát, pakbtaxel, rttónavig és szakvmavir köréből választott,
22. Az 1-21. igénypontok bármelyike szerinti bőrön át alkalmazható készítmény gyógyszeréit váló alkalmazásra,
23. Az 1 -2 !. igénypontok bármelyike szerinti bőrön át alkalmazható készítmény egy alkalmazott hatóanyag beadására való alkalmazásm,
24. Az 1, igénypont szerinti bőrön át alkalmazható készítmény, ahol a zsircsopori egy ieihetkn zsírsav.
25. Az 1. igénypont szerinti bőrön át alkalmazható készítmény, ahol a zsírcsoport egy többszörösen telítetlen zsírsav, 24 A 12. Igénypont szerinti bőrön át alkalmazható készttmáöy, ahol a polipeptid hormon öxltócln, vazopressxm, nteianoeba-sIlpplÄ hormon, imriiköiröpim lipotropm, pmMmirig^seífentö kormon, növekedési hormon, prolaktm, Inteinizalo hPmoo, huma» chorionic gonadotropin, thszőérést serkentő kormon, korriloixopiP íélpahadíio faktor. gonádotroglm Mtóxkhtd takten ptolaktlnt ösÄtM toktor, polakiät gátló faktor, Âpkedési homroat felszabadító faktor; tirsotmpmt éémMM faktor, kalcitonio., kaidtonfn gén-rokon pepid, atelilkpajzsaürigjf lronaon, glnkagomazerô pepiid I (GOM), glnkozinggö ΙοζοΗηοόόρ :póllpépiM,: gasztrÍB, szókrébn, koleelsztokmin, mötilin, vazoaktfv intósztinábs pepiid, ilmpyag,: lasnyálmitlgy potipepíid, pepid tirozin tirozin, neuropepùd iirozin, amphiregulin (â-EICIk lozolm glokagop, piacontâlts laktogép, relaxia, angioîonztn I), pitvari nätriuretlköS';|i!i^>f|<|) és;molposinfc&amp;fbdî választott.
27. Az L igénypofit nzerinfi bőrön ál alkalmazható készítmény, ahol az alkalmazott hatóanyag égy nem-pèptid: &amp;Öí&amp;ob.
28, Az f... igény pont szerinti bőrön át alkalmazható készítmény, ahol a hormon OfôÂ irijód-titonm, ösztradiol ösztron. progeszteron, íeszíoszteron, koriizol, koríikoszteron, aliosztërOn, opineMópBötépmóífiü, os kálóiról köréből választott. Ä Λ |4 igénypont szerinti borörl át alkalmazható késdtmény, ahol M érzésmienlto artlMn, prokain, íettákátm klOZöpmkain és bohzokalrg BovökÄ, mepívakalm Impívakalm benzokaim és lidokain köréből választolt. 3§. A I S. igénypont szerinti bőrön át alkalmazható készítmény; ahol a Ipdalomcsrllapíié tramadol sósav, föntánl!, motamlzol, morfió-szulíak kétofolao izömetamín, tnfefmdom ppkodott, morfin, lokoptóíen, Capsaiein, és BosweliM köriből választott. 3|, A 20. igénypont szerinti bőrön át alkalmazható készítmény, ahol az. inmnm választ módosító anyag pnrinszármazékok, ademnszármazekok,: ólklosporio és OpGs kömből választott
HUE05826138A 2004-05-28 2005-05-25 Mixtúra alacsony és magas molekulatömegû vegyületek transzdermális beadásához HUE026644T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2004/017169 WO2005039464A1 (en) 2003-10-10 2004-05-28 Transdermal high and low molecular weight compounds
US10/856,567 US7220427B2 (en) 1998-07-08 2004-05-28 Mixture for transdermal delivery of low and high molecular weight compounds

Publications (1)

Publication Number Publication Date
HUE026644T2 true HUE026644T2 (hu) 2016-07-28

Family

ID=37500258

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE05826138A HUE026644T2 (hu) 2004-05-28 2005-05-25 Mixtúra alacsony és magas molekulatömegû vegyületek transzdermális beadásához

Country Status (8)

Country Link
US (2) US20080154210A1 (hu)
EP (1) EP3001990A1 (hu)
AU (1) AU2005294805B2 (hu)
DK (1) DK1765310T3 (hu)
ES (1) ES2560449T3 (hu)
HK (2) HK1102290A1 (hu)
HU (1) HUE026644T2 (hu)
PT (1) PT1765310E (hu)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070248635A1 (en) * 2006-04-20 2007-10-25 Southerlee Incorporated Green tea jewelry
AU2009255619A1 (en) * 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
WO2010039949A1 (en) 2008-10-02 2010-04-08 Mylan Inc. Method of making a multilayer adhesive laminate
ES2755718T3 (es) * 2009-10-16 2020-04-23 Sixtem Life S R L Dispositivo para dosificar una o más sustancias de tratamiento para la piel
MX2012011262A (es) 2010-04-01 2013-02-11 Pharmanest Ab Composiciones anestesicas termogelificantes.
DE202010012043U1 (de) * 2010-08-31 2010-11-11 Sanderstrothmann Gmbh Vorrichtung zur Dosierung einer säurehaltigen Zusammensetzung
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
EP2753179A4 (en) * 2011-09-09 2015-03-04 Univ Leland Stanford Junior TOPICAL FORMULATIONS OF ITRACONAZOLE AND USES THEREOF
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
WO2014018874A1 (en) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Method for treating skin cancer
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
CA2893768C (en) 2012-12-07 2021-08-24 Sambria Pharmaceuticals, Llc Topical preparation for pain relief
US10265283B2 (en) 2012-12-07 2019-04-23 Sambria Pharmaceuticals, Llc Topical composition and delivery system and its use
WO2014106048A2 (en) * 2012-12-31 2014-07-03 Jrx Biotechnology, Inc. Liquid topical pharmaceutical nano-emulsion formulations
KR101622382B1 (ko) 2013-02-27 2016-05-19 (주)내츄럴엔도텍 경피 흡수 촉진제 및 그의 용도
WO2014133344A1 (ko) * 2013-02-27 2014-09-04 주식회사 내츄럴엔도텍 경피 흡수 촉진제 및 그의 용도
US9125892B2 (en) * 2014-02-03 2015-09-08 George D. Petito Composition for reduced scar formation of wounds
US20200375849A1 (en) * 2019-05-28 2020-12-03 Cmpd Licensing, Llc Devices and methods for providing medication
CN108024914A (zh) 2015-09-17 2018-05-11 Jrx生物技术有限公司 改善皮肤的水合作用或润湿作用的方法
GB2564026B (en) * 2016-02-03 2022-07-13 Sbg Medical Tech Inc Topical composition and delivery system and its use
EP3518672A4 (en) * 2016-09-29 2020-05-06 JRX Biotechnology, Inc. METHOD AND COMPOSITIONS FOR MODIFYING PLANT GROWTH AND REDUCING THE WATER CONSUMPTION OF PLANTS
US10576256B2 (en) * 2016-12-13 2020-03-03 Becton, Dickinson And Company Antiseptic applicator
RU2694501C1 (ru) * 2018-01-16 2019-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Тест-система для обнаружения генома возбудителя ротовируса типа А у сельскохозяйственных животных с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени
US11634368B2 (en) 2018-03-28 2023-04-25 Jrx Biotechnology, Inc. Agricultural compositions
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
WO2020205848A1 (en) * 2019-04-01 2020-10-08 Geltor, Inc. Topical formulations of recombinant collagens
US11793981B2 (en) 2020-05-21 2023-10-24 Equilibrate Therapeutics, LLC Microneedle device for control of thyroid hormone levels
CN111529460B (zh) * 2020-06-27 2023-03-28 同芙集团(中国)股份有限公司 一种面膜组合物、面膜及其制备方法
CN113117359B (zh) * 2021-03-05 2022-08-26 湘雅生物医药(湖州)有限公司 一种用于胶原蛋白提取用的无菌式蒸馏瓶
CN113336842A (zh) * 2021-04-14 2021-09-03 海南三元星生物科技股份有限公司 一种胶原蛋白肽的制备方法
WO2024064264A2 (en) * 2022-09-21 2024-03-28 Lile Method Research, Llc Compositions and methods for increasing glutathione levels

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829641A1 (de) * 1988-09-01 1990-03-15 Roecar Holdings Nv Transdermal anwendbare pharmazeutische zubereitungen mit sterolinen und/oder spiroketalinen
US5297562A (en) 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
US5614212A (en) 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
US5840746A (en) 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
DE19509079A1 (de) * 1995-03-15 1996-09-19 Beiersdorf Ag Kosmetische oder dermatologische Mikroemulsionen
JP3380368B2 (ja) 1995-06-05 2003-02-24 三菱電機株式会社 車両用盗難防止装置
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
JPH09255926A (ja) 1996-03-26 1997-09-30 Diatex Co Ltd 粘着テープ
US5891651A (en) 1996-03-29 1999-04-06 Mayo Foundation For Medical Education And Research Methods of recovering colorectal epithelial cells or fragments thereof from stool
US5861268A (en) 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5708038A (en) 1996-06-13 1998-01-13 Univera Pharmaceuticals, Inc. Method of using aloe vera as a biological vehicle
NZ329798A (en) 1996-07-03 1999-04-29 Japan Energy Corp Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
US5936107A (en) 1996-12-09 1999-08-10 Henkel Kommanditgesellschaft Auf Aktien Process for the production of fatty acid polyethylene glycol esters
EP0894797A4 (en) 1997-01-09 2001-08-16 Terumo Corp NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS
US5945446A (en) 1997-02-10 1999-08-31 Laubc Biochemicals, Corporation Process for preparing synthetic soil-extract materials and medicaments based thereon
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6300508B1 (en) 1997-07-30 2001-10-09 Henkel Kommanditgesellschaft Auf Aktien Thickened aqueous surfactant solutions
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
EP1035123B1 (en) 1997-11-28 2003-08-20 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compounds
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6946144B1 (en) * 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
WO2000075304A1 (fr) 1999-06-08 2000-12-14 Aventis Pasteur Oligonucleotide immunostimulant
DK1200580T3 (da) 1999-08-13 2005-04-11 Hybridon Inc Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
PT1233782E (pt) 1999-12-01 2009-02-13 Novartis Vaccines & Diagnostic Estimulação da produção de anticorpos específicos para o hcv
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1242441A4 (en) 1999-12-17 2004-04-14 Merck & Co Inc POLYNUCLEOTIDE VACCINES EXPRESSING CODON-OPTIMIZED NEF HIV-1 PROTEIN AND MODIFIED HIV-1 NEF PROTEIN
WO2001046393A2 (en) 1999-12-21 2001-06-28 E.I. Du Pont De Nemours And Company Aspartate kinase
SK11202002A3 (sk) 2000-02-09 2003-03-04 Hokuriku Seiyaku Co., Ltd. Deriváty 1H-imidazopyridínu
DE10036282A1 (de) 2000-07-26 2002-02-07 Bosch Gmbh Robert Verfahren und Vorrichtung zur Steuerung einer Antriebseinheit
UA79764C2 (en) 2001-11-27 2007-07-25 Anadys Pharmaceuticals Inc 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2004058808A2 (en) 2002-03-22 2004-07-15 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against hantavirus infections
US20030235610A1 (en) * 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
EP1578766B1 (en) 2002-12-03 2013-02-13 University of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
AU2003303561A1 (en) 2002-12-27 2004-07-29 Collins And Aikman Products Co. Trunk compartment latch cover
MXPA05010255A (es) 2003-03-24 2005-12-14 Scripps Research Inst Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas.
WO2004110483A1 (en) 2003-05-31 2004-12-23 Yiyou Chen Method and composition of a novel vaccine design for the prevention and treatment of sars
US9507404B2 (en) 2013-08-28 2016-11-29 Via Technologies, Inc. Single core wakeup multi-core synchronization mechanism

Also Published As

Publication number Publication date
PT1765310E (pt) 2016-03-01
AU2005294805B2 (en) 2012-02-16
EP3001990A1 (en) 2016-04-06
HK1222789A1 (zh) 2017-07-14
DK1765310T3 (en) 2016-01-11
HK1102290A1 (zh) 2007-11-16
US20140200531A1 (en) 2014-07-17
ES2560449T3 (es) 2016-02-19
AU2005294805A1 (en) 2006-04-20
US20080154210A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
DK1765310T3 (en) MIXING for transdermal delivery of LAV AND HØJMOLEKYLVÆGTFORBINDELSER
US7300666B2 (en) Mixture for transdermal delivery of low and high molecular weight compounds
US6946144B1 (en) Transdermal delivery system
KR100648536B1 (ko) 침투 보강 및 자극 감소를 위한 계
JP5144277B2 (ja) 局所用生体付着性製剤
JP5731446B2 (ja) 局所用生体付着性製剤
TW201521758A (zh) 用於使皮膚回春之胜肽及其使用方法
EP1765310B1 (en) A mixture for transdermal delivery of low and high molecular weight compounds
TR201808178T4 (tr) Aktif ajanların transdermal dağıtımı için bileşimler.
JP2009184951A (ja) 皮膚外用剤組成物
PT1853303E (pt) Composições estabilizadas para administração tópica, e métodos para a sua preparação
JP5732471B2 (ja) 溶媒混合物およびビタミンｄ誘導体から成る医薬品組成物または類似体
EP1684681B1 (en) A mixture for transdermal delivery of low and high molecular weight compounds
WO2000002601A2 (en) Transdermal delivery system
AU2012200101A1 (en) A mixture for transdermal delivery of low and high molecular weight compounds
JP2016530287A (ja) 過角化性の皮膚病変の治療を目的とする、角質溶解薬としてのトルフルオロ酢酸またはその生理学的に許容される塩の使用